T2D commonly refers to type 2 diabetes, a chronic metabolic disease characterized by insulin resistance and impaired insulin secretion leading to hyperglycemia. It represents the large majority of diabetes cases.
A secondary analysis of the SOUL trial shows oral semaglutide significantly lowers heart failure-related events in type 2 diabetes patients with preexisting heart failure, particularly those with preserved ejection fraction, without increasing serious adverse events.
Eli Lilly is developing multiple next-generation obesity treatments, including oral GLP-1 drug orforglipron expected to launch in Q2 2026, as competition intensifies in a market projected to reach $95 billion by 2030.
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07229482 |
Potatoes, Type 2 Diabetes, and Cardiometabolic Health |
NOT_YET_RECRUITING | NA |
| NCT07005362 |
Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D |
RECRUITING | |
| NCT06692153 |
Embecta AID System in Adults With Type 2 Diabetes |
WITHDRAWN | NA |
| NCT06445335 |
Prevalence of NAFLD in T2DM Patients |
ACTIVE_NOT_RECRUITING | NA |
| NCT05980754 |
Clinical Study on Exploring High Risk Factors Inducing the Progress of Diabetes |
NOT_YET_RECRUITING | |
| NCT05760677 |
Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM |
UNKNOWN | PHASE1 |
| NCT05662332 |
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) |
COMPLETED | PHASE3 |
| NCT05536804 |
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05260021 |
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both |
COMPLETED | PHASE3 |
| NCT04501341 |
BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients |
UNKNOWN | PHASE1/PHASE2 |
